Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
2.6.2024 15:30:00 EEST | Business Wire | Press release
Denodo, a leader in data management, announced that it has integrated NVIDIA NIM inference microservices into the Denodo Platform, as part of its focus on bolstering its rapidly expanding artificial intelligence (AI) capabilities.
The Denodo Platform's logical data management capabilities, combined with NVIDIA NIM, enable enterprise customers to:
- Rapidly curate and transform data into AI-ready pipelines to feed large language models (LLMs)
- Improve model accuracy and combat hallucinations by accessing trusted enterprise data through retrieval augmented generation (RAG) pipelines.
- Simplify secure, real-time access to distributed enterprise knowledge for generative AI applications
- Maintain data privacy/security and enforce granular access controls for AI models that access organizational data
- Fast-track AI/ML deployments from data prep to model scoring with NVIDIA NeMo, leveraging an integrated data fabric for enterprise data input into this process
NVIDIA NIM is a collection of cloud-native microservices that simplify and accelerate the deployment of generative AI models across a variety of environments, including the cloud, on-premises data centers, and workstations. It connects the power of the latest foundational AI models, securely deployed on NVIDIA’s accelerated infrastructure, with enterprise customers everywhere.
The Denodo Platform’s integration of NVIDIA NIM helps customers seamlessly leverage advanced AI capabilities within their data management workflows. It also helps enable enterprises to deploy and scale generative AI applications with unprecedented speed and efficiency. Key use cases include improved analytics and robust AI-driven insights across such verticals as financial services, healthcare, retail, and manufacturing, accelerating time to insight from diverse data sources. As an NVIDIA Metropolis partner, Denodo is working to deploy vision AI and vision language model (VLM) NIM microservices to streamline industrial processes and increase worker safety.
Using the Denodo Platform with NVIDIA NeMo can significantly boost SQL query generation accuracy for LLMs. RAG capabilities enable more trustworthy responses by enabling models to retrieve relevant knowledge from the data fabric before generating output, and the Denodo Platform helps to simplify and accelerate data access, while reducing errors, when models query the platform.
By integrating NVIDIA NIM, Denodo helps ensure that customers will be able to maintain full control over their AI deployments, whether on premises or in the cloud. The integration is set to deliver significant business benefits, including accelerated time to value and enhanced security for AI applications.
“I am thrilled by this integration, and I think it's a sign of the direction in which Denodo's logical data management capabilities can take us,” said Narayan Sundar, Senior Director-Strategic Alliances at Denodo. “Denodo is at the forefront of supporting RAG-enabled GenAI applications with real-time, governed, trusted data from an organization’s vast data estates, and I look forward to seeing the innovations, as they start to emerge, from enterprise customers that leverage the Denodo Platform with NVIDIA NIM integration.”
Learn more about the Denodo Platform with NVIDIA NIM integration.
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602559183/en/
Contact information
Media
pr@denodo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
